Impact of MIgalastat TheRApy on CaRdiac Function in patiEnts With Fabry's Cardiomyopathy (MIRACRE-Fabry Trial)

Overview

This is an observational study. No treatment or intervention will be assigned to the subjects. All patients will receive full standard of care concomitant medication for the treatment of their cardiac condition. 20 patients with genetically confirmed Anderson-Fabry disease who have a plan to start Migalastat will undergo 2D strain, diastolic stress echocardiography, LV vortex flow analysis, and CMR at baseline and after 2 year of treatment with Migalastat for follow-up.

1. Objectives - to evaluate the impact of chaperone therapy on LV diastolic function and flow in patients with Fabry's cardiomyopathy using LV 2D strain, diastolic stress echocardiography, LV vortex flow and CMR. 2. Primary/Secondary Endpoint A. Primary endpoint: \- Change of peak exercise E/E' by diastolic stress echocardiography, global longitudinal strain and LV vortex flow parameters at 2 year follow up. B. Secondary endpoints: * Changes of extracellular volume by CMR (T1 mapping) at 2 year follow up * Evaluation of the degree of the resting LV diastolic function * Evaluation of global and regional LV strain * Other echo-parameters; LV mass index at baseline, 2 year follow up, reduction of peak exercise E/E prime at 2 year follow up * Changes of quality of life using questionnaire * Change of peak VO2, exercise time, AT by diastolic stress echocardiography at 2 year follow up * Change in T1 baseline (myo, ms) \& T1 baseline (blood, ms) T1 postcontrast (myo, ms) \& T1 baseline (blood, ms) by CMR 3. Study Methods -Study Design: This is an observational study. No treatment or intervention will be assigned to the subjects. All patients will receive full standard of care concomitant medication for the treatment of their cardiac condition. 20 patients with genetically confirmed Anderson-Fabry disease who have a plan to start Migalastat will undergo 2D strain, diastolic stress echocardiography, LV vortex flow analysis, and CMR at baseline and after 2 year of treatment with Migalastat for follow-up.

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Central Contacts